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SUMMARY 
 
Breast cancer is the single most frequent event in Li-Fraumeni syndrome, 
accounting for more than 25% of all tumors in affected families. This syndrome is a rare 
inherited cancer susceptibility disease associated with germline mutations in the TP53 
gene. Recent studies have shown that breast cancers in women with Li-Fraumeni syndrome 
are commonly hormone receptor and HER2-positive, the latter being rare in BRCA1/2 
mutation carriers, suggesting that HER2 amplification or over-expression in a young woman 
may be a useful criterion for identifying carriers of germline TP53 mutations. However, only 
a minority of early-onset HER2-positive breast cancers are explained by the existence of 
germline mutations in the TP53 gene. 
The aims of this work were to identify the contribution of germline TP53 mutations 
for early-onset HER2-positive breast cancer, to identify other genes with germline mutations 
in patients with early-onset HER2-positive breast cancer, to define the genetic testing 
criteria to complement established recommendations and to compare the HER2 
amplification pattern in carcinomas from women with pathogenic germline mutations in the 
TP53 gene compared with women with other germline variants. We therefore performed 
Sanger sequencing in peripheral blood samples from 88 women and gene-panel next-
generation sequencing (NGS) in additional 36 women, all with HER2-positive breast cancer 
diagnosed until the age of 40. HER2 amplification analyses was performed in seven tumors 
from patients with germline mutations. 
Of the 124 patients, five were shown to carry heterozygous variants in the TP53 
gene, namely, c.642T>G, p.(His214Gln); c.524G>A, p.(Arg175His); c.559+19_559+34del, 
p.?; c.383delC, p.(Pro128LeufsTer42); and c.935C>G, p.(Thr312Ser). Two of the five TP53 
variants are classified as deleterious mutations and the remaining three are variants of 
uncertain significance (VUS), with the probands carrying the pathogenic mutations showing 
pedigrees with various early-onset cancers that are not among the most typical in Li-
Fraumeni syndrome. Additionally, two of the 36 patients tested by NGS were shown to have 
deleterious mutations in other genes, namely, the mutation c.9105T>A, p.(Tyr3035Ter), in 
the BRCA2 gene and the mutation c.295C>T, p.(Gln99Ter), in the FANCA gene. All tumors 
were confirmed as HER2-amplified (HER2/CEP17 ≥ 2.0), with the tumors of the patients 
with TP53 pathogenic mutations showing the highest degree of HER2 amplification.  
We conclude that, although most breast cancers in women with Li-Fraumeni 
syndrome are HER2-positive, germline TP53 mutations account for only a small proportion 
of early-onset HER2-positive breast cancer and other genes, like BRCA2 and FANCA, may 
also contribute to the pathogenesis of this breast cancer subtype. Taking into account the 
potential clinical impact, women diagnosed with early-onset HER2-positive breast cancer, 
XX 
especially those having first-degree relatives with any cancer until the age of 45 years, as 
well as all cases of breast cancer diagnosed before age 30 irrespective of family history, 
should receive genetic counseling and genetic testing that includes TP53. Furthermore, we 
show evidence that breast carcinomas from patients with deleterious TP53 germline 
mutations might show higher HER2 amplification ratios than those from patients with other 
germline variants. 
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RESUMO 
 
O cancro da mama é o evento mais frequente na síndrome de Li-Fraumeni, 
correspondendo a mais de 25% de todos os tumores diagnosticados em famílias afetadas. 
Esta síndrome é uma doença hereditária rara de suscetibilidade para o desenvolvimento 
de cancro associada a mutações germinativas no gene TP53. Estudos recentes têm 
mostrado que os cancros da mama em mulheres com síndrome de Li-Fraumeni são 
frequentemente positivos para os recetores hormonais e para o gene HER2. Cancros da 
mama HER2-positivos são raros em portadores de mutações nos genes BRCA1/2, o que 
sugere que a amplificação ou a sobre-expressão de HER2 numa mulher jovem pode ser 
um critério útil para a identificação de portadores de mutações da linha germinativa no gene 
TP53. No entanto, apenas uma minoria dos cancros da mama HER2-positivos de início 
precoce são explicados pela existência de mutações germinativas no gene TP53. 
Os objetivos deste trabalho foram identificar a contribuição das mutações 
germinativas no gene TP53 para cancro da mama HER2-positivo em idade jovem; 
identificar outros genes com mutações germinativas em pacientes com cancro da mama 
HER2-positivo em idade jovem; definir os critérios de testes genéticos para complementar 
as recomendações estabelecidas; e ainda comparar o padrão de amplificação do gene 
HER2 em carcinomas de mulheres com mutações patogénicas germinativas no gene TP53 
com o de mulheres com outras variantes germinativas. Foi realizada sequenciação de 
Sanger em amostras de sangue periférico de 88 mulheres e testado um painel de genes 
por sequenciação de nova geração (NGS) em 36 mulheres, todas com cancro da mama 
HER2-positivo diagnosticado até a idade de 40 anos. A análise da amplificação do gene 
HER2 foi realizada em sete tumores de doentes com variantes na linha germinativa. 
Dos 124 doentes analisados, cinco eram portadores de variantes heterozigóticas 
no gene TP53, nomeadamente, c.642T>G, p.(His214Gln); c.524G>A, p.(Arg175His); 
c.559+19_559+34del, p.?; c.383delC, p.(Pro128LeufsTer42); e c.935C>G, p.(Thr312Ser). 
Duas das cinco variantes foram classificadas como mutações deletérias e as três restantes 
como variantes de significado desconhecido, com os probandos com mutação patogénica 
no gene TP53 a mostrarem pedigrees com vários cancros de início precoce fora do 
espectro mais típico da síndrome de Li-Fraumeni. Além disso, dois dos 36 doentes testados 
por NGS mostraram ter mutações deletérias em outros genes, nomeadamente, a mutação 
c.9105T> A, p. (Tyr3035Ter), no gene BRCA2 e a mutação c.295C> T, p. (Gln99Ter), no 
gene FANCA. Todos os tumores foram confirmados como tendo amplificação do gene 
HER2 (HER2/CEP17 ≥ 2,0), sendo que os tumores dos doentes com mutação patogénica 
no gene TP53 apresentaram maior grau de amplificação. 
XXIV 
Concluímos que, embora a maioria dos cancros da mama em mulheres com 
síndrome de Li-Fraumeni sejam HER2-positivo, as mutações germinativas no gene TP53 
representam apenas uma pequena proporção do cancro da mama HER2-positivo de início 
precoce, sendo que outros genes, como o BRCA2 e o FANCA, podem também contribuir 
para a patogénese deste subtipo de cancro da mama. No entanto, considerando o potencial 
impacto clínico, as mulheres diagnosticadas com cancro da mama HER2-positivo em idade 
jovem, especialmente aquelas que têm parentes em primeiro grau afetados com qualquer 
tipo de cancro até à idade de 45 anos, bem como todos os casos de cancro da mama 
diagnosticados antes dos 30 anos, devem receber aconselhamento genético e ser 
submetidas a testes genéticos que incluam a análise ao gene TP53. Concluímos, ainda, 
que os carcinomas da mama de doentes com mutações patogénicas no TP53 podem 
apresentar rácios de amplificação do gene HER2 superiores aos de doentes com outras 
variantes na linha germinativa. 
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I. Introduction 
 
Cancer is a group of diseases characterized by uncontrolled cell division and 
dissemination of abnormal cells (Chambers et al., 2002; Preston-Martin et al., 1990). If 
cancer is detected after the spread of cancer cells, treatments are much less successful 
and it can result in death (Chambers et al., 2002). Cancer is caused by extrinsic factors 
(tobacco, infectious organisms, drugs) and/or intrinsic factors (hormones, inherited genetic 
mutations, immune conditions) (Torre et al., 2015). Surgery, radiation, chemotherapy, 
hormone therapy, immune therapy, and targeted therapy are the most common treatments 
used in cancer (American Cancer Society, 2015). 
Cancer is currently the major public health problem, with 14.1 million of new cases 
and 8.2 million deaths in the world, during the year 2012 (Ferlay et al., 2015). In 2025 are 
estimated 19 million new cases per year in the world and 24 million of new cases will be 
diagnosed by 2035 (Coleman, 2015). In the year 2012, the most commonly diagnosed 
cancers were lung (1.82 million), breast (1.67 million), and colorectal (1.36 million) (Ferlay 
et al., 2015).  
 
 
I.1 Breast Cancer 
 
I.1.1 Breast Cancer Epidemiology 
Considering both sexes, breast cancer was the second most frequent cancer in the 
world in 2012 and the most common invasive tumor diagnosed among women, both in 
developed and developing countries (Figure I.1) (Ferlay et al., 2015). 
Excluding skin cancers, breast cancer is the most common cancer diagnosed 
among women in Europe, with an incidence of 69.9 per 100 000 in 2012. This cancer 
represents the leading cause of cancer mortality, with a mortality of 16.1 per 100 000 (Figure 
I.2a). In Portugal, as in Europe, breast cancer is the most common cancer diagnosed among 
women, with an incidence of 67.6 per 100 000 and a mortality of 13.1 per 100 000 in 2012 
(Figure I.2b) (IARC, GLOBOCAN 2012). 
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Figure I.1. Estimated age-standardised incidence rates of breast cancer in the world in women [Adapted 
from GLOBOCAN 2012 (IARC)] 
 
 
 
Figure I.2. Estimated age-standardized incidence and mortality rates among women: a. in Europe and 
b. in Portugal. ASR: age-standardized rates [adapted from GLOBOCAN 2012 (IARC)] 
 
 In northern Portugal, according to the Northern Region Cancer Registry (RORENO) 
data from 2010, breast cancer was the most commonly diagnosed cancer among women, 
accounting for over a quarter of all tumors diagnosed (29.2%) (RORENO, 2015). 
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I.1.2 Etiology and Risk Factors 
 Breast cancer has been attributed to a combination of genetic susceptibility and 
other patient factors, including age and reproductive, hormonal and lifestyle features (diet, 
smoking, alcohol, weight). Although the specific causes are not yet fully understood, gender 
is the greatest risk factor, as breast cancer occurs 100 times more frequently in women than 
men (Richie and Swanson, 2003). Another well-documented risk factor for breast cancer 
(and for many other cancers) is age. The incidence of breast cancer is low before the age 
of 35 (less than 5%), after which it increases linearly with age (Senkus et al., 2013; 
Singletary, 2003). Early menarche, late menopause and null parity also are associated with 
an increased risk of developing breast cancer (Hulka and Moorman, 2001; Singletary, 
2003). 
 Furthermore, alcohol consumption and overweight have also been reported quite 
consistently as breast cancer risk factors. Alcohol consumption at a level of one to two 
drinks per day modestly increases breast-cancer risk (Singletary, 2003). In premenopausal 
women, body mass index is not a risk factor for breast cancer incidence, but in 
postmenopausal women the relative risk of breast cancer incidence is higher in overweight 
women (Hulka and Moorman, 2001; Singletary, 2003). 
Family history is one of the most well-established breast cancer risk factors. A 
woman with a first-degree relative with breast cancer has an approximately two- to threefold 
excess risk of developing the disease (Hulka and Moorman, 2001). In turn, if a woman has 
multiple relatives affected, the risk of developing breast cancer further increases. It is 
estimated that approximately 7% of all breast cancers are due to inherited gene alterations 
(Hulka and Moorman, 2001). 
 
I.1.3 Diagnosis and Treatment 
 Breast cancer may be diagnosed as the result of a screening program. The 
underlying principle for breast cancer screening is that it allows the detection of tumors at a 
pre-clinical stage, in order to improve the chance of survival. The European Union 
recommends biannual mammography screening in the age group of 50 to 69 years, since 
in this age group the regular examination has resulted in reduction of breast cancer mortality 
(Senkus et al., 2013). A mammography is an X-ray picture of the breast often used as a 
screening tool, but one should take into account the false-positive findings that require 
additional imaging or histopathological assessment (Nounou et al., 2015). The diagnosis of 
breast cancer is based on clinical examination in combination with imaging, and confirmed 
by pathological assessment (Senkus et al., 2013). 
Breast cancer can be classified into in situ carcinoma or invasive carcinoma. In situ 
carcinoma may be further distinguished in lobular (LCIS) or ductal (DCIS), both having no 
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invasion of the underlying basement membrane. As would be expected with such localized 
and confined malignancy, there is little potential for metastases formation (Richie and 
Swanson, 2003). When there is infiltration beyond the basement membrane, the 
malignancy is considered invasive (or infiltrating) and it comprises several histological 
subtypes: invasive carcinoma of no special type, invasive lobular carcinoma, tubular 
carcinoma, cribriform carcinoma, mucinous carcinoma, carcinoma with medullary features, 
carcinoma with apocrine differentiation, invasive micropapillary carcinoma and metaplastic 
carcinoma of no special type (Lakhani et al., 2012). 
Breast cancer has been described as a heterogeneous disease that displays a 
variety of subtypes with different expression profiles that have substantial implications for 
prognosis and survival rates (Carraro et al., 2013). The molecular classification of breast 
cancer by gene-expression patterns established four major breast cancer subtypes: the 
Luminal A, Luminal B, Basal-like and the HER2-positive (Table I.1) (Ades et al., 2014; Perou 
et al., 2000; Skibinski and Kuperwasser, 2015; Sorlie et al., 2001; Sorlie et al., 2003). These 
subtypes differ in genomic complexity, key genetic alterations and clinical prognosis (Banerji 
et al., 2012). 
 
Table I.1. Breast cancer molecular subtypes [Adapted from Ades et al., 2014; Perou et al., 2000; 
Skibinski and Kuperwasser, 2015; Sorlie et al., 2001 and Sorlie et al., 2003] 
Subtypes Characteristics 
Luminal A Estrogen receptor positive, HER2-negative, Ki-67 protein low, and progesterone 
receptor high. 
Luminal B Estrogen receptor positive, HER2-positive or negative, and Ki-67 protein high or 
progesterone receptor low. 
Basal-like Typically lacks expression of the molecular targets that confer responsiveness to 
highly effective targeted therapies, such as tamoxifen and aromatase inhibitors or 
trastuzumab. 
HER2-positive Overexpression of HER2 protein, which is highly associated with HER2 gene 
amplification. This subtype is more heterogeneous with the majority being negative for 
hormone receptors but a sizeable minority showing expression of estrogen or 
progesterone receptor. 
 
 
Breast cancer is usually treated through combinations of different therapies, such as 
surgery, radiation therapy, chemotherapy, hormone therapy, targeted therapy and 
bisphosphonates. Breast conserving surgery is the most common approach in the treatment 
of localized breast cancer, being possible in about 60 to 80% of cancers diagnosed in 
Central Europe. However, in some patients, mastectomy is still carried out because of tumor 
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size (relative to breast size), tumor multicentricity, inability to obtain negative surgical 
margins after multiple resections, prior radiation to the chest wall or breast, inability to 
perform radiation therapy, or even by patient choice. Radiation therapy is a process in which 
cancer cells are directly exposed to high levels of radiation. Whole breast radiation therapy 
alone reduces the risk of local recurrence by two-thirds (Nounou et al., 2015; Senkus et al., 
2013). 
The decision on systemic adjuvant therapies should be based on the molecular 
classification (Figure I.3). All luminal cancers should be treated with endocrine therapy. 
Most luminal A tumors require no chemotherapy, except those with highest risk of relapse. 
Similarly, indications for chemotherapy within luminal B HER2-negative tumors depend on 
the risk of relapse (taking into account the tumor extent, your grade, cell proliferation and 
vascular invasion), presumed responsiveness to endocrine therapy and patient choice. 
Luminal B HER2-positive tumors are treated with chemotherapy, endocrine therapy and 
anti-HER2 therapies. The triple-negative tumors are treated with chemotherapy, and HER2-
positive tumors are also treated with chemotherapy coupled with anti-HER2 therapies 
(Nounou et al., 2015). 
 
 
Figure I.3. The adjuvant therapy options according to the molecular subtypes [Adapted from Nounou et 
al., 2015] 
 
A
d
ju
v
a
n
t 
th
e
ra
p
y
 s
tr
a
te
g
ie
s
 f
o
r 
b
re
a
s
t 
c
a
n
c
e
r
Luminal A
Chemotherapy is 
considered in case of high 
tumor burden or grad 3
Endocrine therapy for the 
majority of cases
Luminal B
HER2-
positive
Endocrine therapy + 
Chemotherapy + Anti-
HER2
HER2-
negative
Endocrine therapy + 
Chemotherapy for the 
majority of cases
HER2-positive
Chemotherapy + Anti-
HER2
Triple negative Chemotherapy
Introduction 
6 
I.1.4 Breast Carcinogenesis 
 The chronic and often uncontrolled cell proliferation, which is the essence of the 
neoplastic disease, involves not only deregulation in the control of cell proliferation, but also 
adjustments on the energy metabolism in order to boost the growth and division of cells. 
Currently, it is widely accepted that normal cells evolve progressively to a neoplastic state 
by acquiring hallmark capabilities: 1) sustaining proliferative signaling; 2) resisting cell 
death; 3) evading growth suppressors; 4) enabling replicative immortality; 5) inducing 
angiogenesis; 6) activating invasion and metastasis; 7) deregulating cellular energetics; and 
8) avoiding immune destruction. Moreover, the acquisition of these hallmarks is possible 
due to two essential characteristics, genomic instability that lead to increased variability 
(mutability), and inflammation (Hanahan and Weinberg, 2011).  
Cancer cells may acquire the ability to sustain a proliferative signal by different 
approaches: 1) generating their growth factors, resulting in autocrine proliferative 
stimulation; 2) sending signals to stimulate normal cells to produce various growth factors; 
3) elevating the levels of protein receptors at the cancer cell surface; 4) through structural 
alterations in receptor molecules that facilitate activation independent of ligand receptor; or 
5) constitutive activation of elements of signaling pathways operating downstream of these 
receptors (Hanahan and Weinberg, 2011). 
In breast cancer, some of these mechanisms have been demonstrated. For 
example, HER2 amplification with resultant HER2 protein overexpression has been shown 
to play a role in sustaining multiple cancer pathways, as self-sufficiency in growth signals. 
HER2 amplification is also involved in sustaining angiogenesis, increasing cell division and 
enhancing invasion and metastization (Slamon et al., 2011). Other mechanisms that 
contribute for the ability of cancer cells to sustain a proliferative signal are mutations in the 
phosphoinositide 3-kinase (PI3K) pathway. These mutations cause resistance to HER2 
targeted therapies by leading to constitutive activation of elements of signaling pathways 
operating downstream of growth factor receptors (Arteaga et al., 2012). In addition to the 
ability to control cellular proliferation signals, cancer cells can also avoid the pathways that 
negatively regulate cell growth. This occurs by inactivation of tumor suppressors such as 
tumor suppressor protein p53 (p53) and retinoblastoma-associated protein (Rb) (Hanahan 
and Weinberg, 2011). Somatic mutations in the TP53 gene are frequent in sporadic basal 
breast cancer subgroups (Rath et al., 2013). 
Genetic mutations are considered the major causes for the development of cancer. 
However, this paradigm has been expanded to incorporate epigenetic regulatory 
mechanisms. The key processes responsible for epigenetic regulation are DNA methylation 
(including global hypomethylation and locus specific hypermethylation), histone 
modifications, chromatin remodeling and post-transcriptional gene regulation by noncoding 
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RNA (microRNAs) (You and Jones, 2012). DNA hypomethylation can be associated with 
gene reactivation and might lead to the upregulation or overexpression of proto-oncogenes, 
while DNA hypermethylation is frequently associated with silencing of suppression of tumor 
suppressor genes and compaction of chromatin. Although breast carcinomas are frequently 
hypomethylated on a genome-wide scale, the number of genes described as 
hypomethylated in breast cancer is relatively small. The endonucleases FEN1, the N-
acetyltransferase NAT1 and the cadherin CDH3 are examples of genes that are 
hypomethylated in primary breast tumors (Jovanovic et al., 2010). On the other hand, more 
than one hundred genes have been reported to be hypermethylated in breast tumors or 
breast cancer cell lines. Many of these genes play important roles in cell-cycle regulation, 
DNA repair, apoptosis, tissue invasion and metastasis, angiogenesis and hormone 
signaling. BRCA1, APC and BCL2 are examples of genes that may be silenced by 
hypermethylated in breast cancer (Jovanovic et al., 2010; Stefansson and Esteller, 2013). 
Another epigenetic alteration in breast cancer is the silencing of RAD51 induced by the 
histone methyltransferase EZH2 (Stefansson and Esteller, 2013). 
 
I.1.5 Hereditary Breast Cancer 
Cancer usually occurs in one of three patterns: inherited, familial or sporadic. It is 
estimate that 5 to 10% of human tumors occur in individuals with an inborn cancer 
susceptibility (Bakry and Malkin, 2013). Some cancer predisposition syndromes that 
comprise breast cancer have been described, and include hereditary breast and ovarian 
cancer (HBOC), hereditary diffuse gastric cancer, and the Cowden, Peutz-Jeghers, and Li-
Fraumeni syndromes (Table I.2). These syndromes are caused by germline mutations in 
the BRCA1 and BRCA2, CDH1, PTEN, STK11, and TP53 genes, respectively (Apostolou 
and Fostira, 2013; Easton et al., 2015; van der Groep et al., 2011). 
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Table I.2. List of the main susceptibility genes for breast cancer development and associated 
syndromes [Adapted from Apostolou and Fostira, 2013; Easton et al., 2015; van der Groep et al., 2011] 
Gene involved Cytoband 
Breast 
cancer risk 
Syndrome Clinical features 
BRCA1 17q21 High 
Hereditary breast cancer and 
ovarian syndrome 
 
Breast cancer, ovarian 
cancer 
BRCA2 13q12.3 High 
Breast cancer, ovarian 
cancer, prostate cancer, 
pancreatic cancer, 
melanoma 
TP53 17p13.1 High Li-Fraumeni syndrome 
Breast cancer, sarcomas, 
brain tumors, adrenocortical 
cancer, leukemia 
ATM 11q22.3 Intermediate 
Ataxia telangiectasia 
syndrome 
Lymphoma, cerebellar 
ataxia, immune deficiency, 
glioma, medulloblastoma (in 
homozygosity); breast 
cancer (in heterozygosity) 
CDH1 16q22.1 Intermediate 
Hereditary diffuse gastric 
cancer syndrome 
Diffuse gastric cancer, 
lobular breast cancer 
PTEN 10q23.31 Intermediate Cowden syndrome 
Breast, thyroid, and 
endometrial carcinomas, 
hamartomatous polyps of 
the gastrointestinal tract 
STK11 19p13.3 Intermediate Peutz-Jeghers syndrome 
Melanocytic macules of the 
lips, oral mucosa and 
perioral region, multiple 
gastrointestinal 
hamartomatous polyps, 
increased risk of breast, 
testis, pancreas and ovarian 
cancer 
NBS1 8q21 Intermediate Nijmegen breakage syndrome 
Microcephaly, growth 
retardation, 
immunodeficiency and a 
marked susceptibility to 
cancer (in homozygosity); 
moderate risk of breast 
cancer (in heterozygosity) 
CHEK2 22q12.1 Intermediate CHEK2- related 
Breast, colorectal, ovarian, 
bladder cancers 
PALB2/FANCN 16p12 Intermediate 
Fanconi anemia 
Aplastic anemia, acute 
myeloid leukemia and 
squamous cell carcinoma (in 
homozygosity); breast 
cancer (in heterozygosity) 
FANCA 16q24.3 Low 
FANCE 6p22-p21 Low 
 
 
Breast cancers developing in individuals with specific hereditary predisposition 
syndromes have been shown to have preferential disease subtypes. For example, the 
majority of BRCA1-associated breast cancers shares the gene expression profile of 
sporadic basal-like tumors (estrogen receptor negative, progesterone receptor negative, 
and HER2-negative) (Masciari et al., 2012). On the other hand, BRCA2-associated breast 
cancers are often estrogen and progesterone receptor positive and HER2-negative 
(Masciari et al., 2012). Furthermore, several recent studies proposed that breast cancers in 
women with Li-Fraumeni syndrome are hormone receptor and HER2-positive (Lee et al., 
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2012; Masciari et al., 2012; Melhem-Bertrandt et al., 2012; Rath et al., 2013; Wilson et al., 
2010). 
Whereas germline mutations in the BRCA1 and BRCA2 genes are clearly the most 
frequent known cause of hereditary breast cancer predisposition (Lalloo et al., 2003; Lee et 
al., 2012; Rapakko et al., 2001; Walsh et al., 2006), some studies demonstrated that TP53 
germline mutations occur at a comparable frequency with BRCA1 and BRCA2 germline 
mutations among very early-onset breast cancer patients (Lee et al., 2012; McCuaig et al., 
2012). However, given the phenotypic differences mentioned above, the breast cancer 
subtype may help to identify and be taken into consideration in the genetic testing criteria.  
 
I.1.6 Germline Mutations in the TP53 gene 
In 1979 p53 was discovered as a protein interacting with the oncogenic T antigen 
from SV40 virus (DeLeo et al., 1979; Kress et al., 1979; Lane and Crawford, 1979). The 
human TP53 gene is located at the short arm of chromosome 17 (17p13.1) and encodes 
for a ubiquitous transcription factor involved in multiple cellular processes, including cell 
proliferation, differentiation, apoptosis, senescence, metabolism, angiogenesis and 
genomic stability (Ganguly and Chen, 2016; Gonzalez et al., 2009; Sorrell et al., 2013). The 
ability to activate transcription is the critical biochemical function of p53 that is intimately 
linked to its tumor suppressor activity (Bakry and Malkin, 2013). This gene contains 11 
exons (first exon is not translated) and encodes a 393 amino acid protein of 53kDa. The 
p53 protein is composed of an acidic N-terminal transactivation domain (amino acids 1-42), 
a proline-rich domain (amino acids 40-92), a centralized DNA-binding domain (amino acids 
101-306), an oligomerization domain (amino acids 307-355) and a basic C-terminal 
regulatory domain (Freed-Pastor and Prives, 2012). The central DNA-binding domain is 
essential to the protein-DNA interaction (Ganguly and Chen, 2016).  
Somatic mutations in the tumor suppressor gene TP53 are frequently observed in 
most types of human cancers (Baker et al., 1989; Nigro et al., 1989), namely in sporadic 
basal and HER2-positive breast cancer subgroups (Rath et al., 2013). On the other hand, 
germline mutations in the TP53 gene are associated with a the phenotypically 
heterogeneous Li-Fraumeni syndrome (Bakry and Malkin, 2013; Lacroix et al., 2006). This 
genetic disease is a rare inherited cancer susceptibility syndrome described in 1969 (Li and 
Fraumeni, 1969), with an autosomal dominant mode of inheritance, and characterized by a 
diversity of early onset tumors (typically sarcomas, brain tumors, adrenocortical cancers, 
leukemias and breast cancers) (Gonzalez et al., 2009).  Surprisingly, the tumor spectrum 
observed in this syndrome is quite different from the tumors usually associated with somatic 
TP53 mutations. In contrast to epithelial cancers where somatic mutations are prevalent, 
patients with Li-Fraumeni syndrome present more commonly tumors of embryonal, 
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neuroectodermal, and mesenchymal cell lineage, with the exceptions of carcinomas of the 
breast, choroid plexus epithelium, and adrenal gland (Bakry and Malkin, 2013). The lifetime 
risk of cancer in Li-Fraumeni syndrome is estimated to be 73% for males and nearly 100% 
for females, the latter mainly due to the increased risk for breast cancer (Chompret et al., 
2000). 
The vast majority of cancer-associated mutations in TP53 are missense alterations, 
which consist in substitutions of one amino acid for another leading to alterations in the 
protein conformation or functionality. This type of mutations is usually transcriptionally 
inactive (Inoue et al., 2012; Sorrell et al., 2013). Other alterations include splice site 
mutations (10.6%), nonsense mutations (7.7%), frameshift insertions and deletions (6.6%), 
as well as other infrequent alterations such as large deletion and deep intronic mutations 
(Figure I.4) (Ganguly and Chen, 2016; Petitjean et al., 2007). 
 
 
Figure I.4. Type of germline mutations in the TP53 gene [Adapted from Ganguly and Chen, 2016] 
 
The great majority of the germline mutations (83.7%) in the TP53 gene occur within 
exons 5-8 (amino acids 126-306), the DNA binding domain, and there are six hotspot 
mutational hotspots at residues Arg175, Arg213, Gly245, Arg248, Arg273 and Arg337 
(Figure I.5) (Ganguly and Chen, 2016). These mutations frequently interfere with DNA 
binding or disrupt the structure of the binding surface, interfering with the protein ability to 
regulate transcription of target genes and consequently losing the ability to mediate most if 
not all of p53's multiple functions (Bakry and Malkin, 2013; Ganguly and Chen, 2016). 
Germline mutations in this domain cause highly penetrant disease with very early onset 
cancers, while mutations outside the DNA binding domain are associated with slower rates 
of tumor development (Sorrell et al., 2013).  
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Figure I.5. Distribution of germline mutations in the TP53 gene Abbreviations: TAD, transactivation 
domain; PRD, proline-rich domain; DBD, DNA-binding domain; TD, tetramerization domain; CTRD, 
C-terminal regulatory domain. [Adapted from the International Association for Research on Cancer 
databases (R18, April 2016)] 
 
Mutations in TP53 can generally be classified as either “DNA contact” (class I) or 
“conformational” (class II) mutants. The first are missense mutations in the amino acid 
residues that normally make direct contact with target DNA sequences, whereas the 
conformational mutants are missense mutations that disrupt the structure of the p53 protein 
on either a local or global level (Freed-Pastor and Prives, 2012; Liu et al., 2010).  
 
I.1.7 HER2-positive Breast Cancer 
The HER2 gene (ERBB2 is the official name provided by the HUGO Gene 
Nomenclature Committee) is located at the long arm of chromosome 17 (17q12) and 
encodes a transmembrane receptor with tyrosine kinase activity but without a known ligand 
(Mano et al., 2007). HER2 belongs to a family of four receptors (EGFR/HER1, HER2, HER3, 
HER4) and it is capable of homodimerization and heterodimerization with any of the other 
three HER proteins. These receptors are involved in regulating cell growth, survival and 
differentiation through activation of the PI3K/Akt and the Ras/Raf/MEK/MAPK pathways 
(Figure I.6) (Alotaibi et al., 2015; Arteaga et al., 2012). 
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Figure I.6. Heterodimer formation of members of the HER family and downstream signaling. 
Abbreviations: AR, amphiregulin; BTC, betacellulin; EPG, epigen; EPR, epiregulin; HB‑EFG, 
heparin-binding EGF-like ligand; NRG, neuregulin [Arteaga et al., 2012] 
 
In young women with breast cancer, 20 to 25% have HER2-positive tumors (Rath et 
al., 2013). The DNA amplification of the HER2 gene can be in tandem arrays, as head-to-
tail or head-to-head repeats, within a chromosome or may occur in extrachromosomal 
entities called double minutes. Double minutes do not contain centromeres and so do not 
bind the mitotic spindle, being likely not distributed equally between daughter cells. Vicario 
and co-workers (2015) showed, in metaphases and nuclei, that the HER2 gene is amplified 
in double minutes or in tandem arrays regions in approximately 30 and 60% of HER2-
positive breast tumors, respectively (Vicario et al., 2015). 
HER2-positive tumors have been associated with poor histological features and 
aggressive behavior, including poorly differentiated and high-grade tumors, high rates of 
cell proliferation, lymph-node involvement, and resistance to certain types of hormonal and 
chemotherapies (Mano et al., 2007; Masciari et al., 2012). The American Society of Clinical 
Oncology (ASCO)/College of American Pathologists (CAP) guidelines recommend that 
HER2 status should be determined for all invasive breast cancers (Wolff et al., 2013). The 
most popular genetic test for assessing HER2 amplification is fluorescence in situ 
hybridization (FISH). However, other techniques can also be used, for example, 
chromogenic in situ hybridization (CISH) and silver in situ hybridization (SISH) (Papouchado 
et al., 2010; Wolff et al., 2007). In clinical diagnosis the most common approach is to screen 
Introduction 
13 
for protein overexpression with immunohistochemistry (IHC) and confirm the presence of 
gene amplification only in equivocal cases (scores of 2+). Despite the regular use of IHC, 
FISH has been considered a more reproductive test (Mano et al., 2007). According to the 
ASCO/CAP guidelines, positive HER2 status is defined as a score of 3+ in IHC and/or a 
HER2/CEP17 ratio of 2.0 or more. A ratio below 2.0 with an average HER2 copy number of 
≥ 6.0 signals per cell is also considered positive. Negative HER2 status is defined as a 
score of 0 or 1+ in IHC and/or a ratio below 2.0 with an average HER2 copy number below 
4.0 signals per cell in dual-probe FISH. Equivocal HER2 status is defined as a score of 2+ 
in IHC and/or a ratio below 2.0 with an average HER2 copy number ≥ 4.0 and < 6.0 
signals/cell (Wolff et al., 2013).  
The outcome for women with HER2-positive tumors has improved markedly after 
the introduction of HER2 targeted therapies. Trastuzumab (Herceptin), a humanized 
monoclonal antibody, was initially shown to improve response rates, time to progression, 
and even survival, with an acceptable safety record, when used alone or added to 
chemotherapy in advanced HER2-positive disease (Pegram et al., 2004; Robert et al., 
2006; Tripathy et al., 2004). Furthermore, it has been approved as adjuvant treatment for 
patients with HER2-positive early stage breast cancer (Gianni et al., 2011; Smith et al., 
2007). Lapatinib is a small molecule tyrosine kinase inhibitor that reversibly inhibits the 
intracellular tyrosine kinase activity of both HER2 and EGFR, suppressing tyrosine 
autophosphorylation and thereby downstream pathways. Preclinical studies showed that 
lapatinib could inhibit the growth of HER2-positive breast cancer cells that were resistant to 
trastuzumab and that this small molecule could enhance the apoptotic effect of anti-HER2 
antibodies (Arteaga et al., 2012; Wolff et al., 2013). In advanced-stage disease, pertuzumab 
(another monoclonal antibody) is approved in conjunction with trastuzumab. This 
monoclonal antibody binds to the HER2 extracellular domain in a different site to 
trastuzumab, and is able to inhibit ligand-induced dimerization of HER2 with its receptor 
partners (Arteaga et al., 2012; Wolff et al., 2013). 
 
I.1.7.1 HER2 Status and Germline TP53 Mutations  
Some recent studies have shown that HER2 amplification or overexpression in a 
young woman may be a useful marker for identifying germline TP53 mutations (Lee et al., 
2012; Melhem-Bertrandt et al., 2012; Rath et al., 2013; Wilson et al., 2010). Wilson et al. 
(2010) and Masciari et al. (2012) showed that 83% and 63%, respectively, of breast cancers 
in women with germline mutations in TP53 gene were positive for HER2 (Masciari et al., 
2012; Wilson et al., 2010), which is significantly higher than the proportion of sporadic 
HER2-positive breast carcinomas (about 20%) (Hanna et al., 2014). Melhem-Bertrandt and 
co-workers (2012) tested 109 female breast cancer patients with invasive carcinoma and 
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compared the pathological characteristics from patients testing positive for a germline 
mutation in TP53 gene with patients testing negative for that gene. They detected that the 
presence of HER2-positive tumors was significantly different between the group with 
germline TP53 mutation (20/30) and the group without mutations (20/79). Estrogen receptor 
and progesterone receptor status were equally distributed between groups. Furthermore, in 
the multicovariate logistic regression analysis, they observed that for each increase in age 
at breast cancer diagnosis there is a decreased likelihood of having a TP53 mutation by 
5%, and in young women diagnosed with HER2-positive disease the odds of having a TP53 
germline mutation increased by nearly 7-fold (Melhem-Bertrandt et al., 2012). However, 
another study reported germline TP53 pathogenic mutations in only 5% of HER2-positive 
breast cancer patients diagnosed before the age of 35 years (Rath et al., 2013).  
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II. Aims 
 
The general aim of this work is to study the mechanisms of inherited predisposition of early-
onset HER2-positive breast cancer. The specific aims are: 
 
 To identify the contribution of germline TP53 mutations for early-onset HER2-
positive breast cancer;  
 To identify other genes with germline mutations in patients with early-onset HER2-
positive breast cancer; 
 To define the genetic testing criteria to complement established recommendations; 
 To compare the HER2 amplification pattern in breast carcinomas from patients with 
pathogenic TP53 germline mutations with that of patients with other germline 
mutations. 
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III. Materials and Methods 
 
III.1 Patients and Sample Collection 
A consecutive series of DNA samples from 88 women with HER2-positive invasive 
breast cancer diagnosed before the age of 41 years were retrospectively selected for 
analysis by Sanger sequencing. Those patients had been referred to the Genetics 
Department of IPO-Porto between June 2006 and June 2014 for TP53 and/or BRCA1 and 
BRCA2 germline mutation analysis. Two of these patients had already done the research 
of germline mutations in the TP53 gene once they meet the Chompret criteria. However, 
the test result was negative for mutation in TP53 gene. 
Another consecutive series of DNA samples from 36 women with HER2-positive 
invasive breast cancer diagnosed before the age of 41 years was collected for gene-panel 
next generation sequencing (NGS), after being to the Genetics Department of IPO-Porto 
between November 2014 and February 2016 for TP53 and/or BRCA1 and BRCA2 germline 
mutation analysis. 
 
 
III.2 TP53 Germline Mutation Analysis 
Screening for germline mutations of the entire coding region (exons 2-11) and 
associated splice junctions of the TP53 gene was performed by Sanger sequencing in 88 
peripheral blood samples. For this purpose, approximately 20 ng of DNA were amplified in 
a solution containing 1x PCR Gold Buffer [Applied Biosystems, Foster City, CA, USA] (150 mM Tris-HCl, 
500 mM KCl), 1.5 mM of MgCl2 [Applied Biosystems], 0.75 mM dNTP mix [Applied Biosystems], 1.25 mM 
of each primer (reverse and forward) [Frilabo, Maia, Portugal], 0.5 U of AmpliTaq Gold [Applied Biosystems] 
and bidestiled sterile water [B. Braun, Foster City, CA, USA] in a final reaction volume of 20 μL. 
Due to the size of the gene in analysis, its amplification was performed using several 
primer sets (Table III.1).  
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Table III.1. Primers used for PCR 
Region amplified Direction Primer pairs Product length 
Exons 2-3 
F 5’-TGTCTCAGACACTGGCATGG-3’ 
447 bp 
R 5’-TGAAAAGAGCAGTCAGAGGAC-3’ 
Exons 2-3 
F 5’-TCTCATGCTGGATCCCCACT-3’ 
344 bp 
R 5’-AGTCAGAGGACCAGGTCCTC-3’ 
Exon 4 
F 5’-TGCTCTTTTCACCCATCTAC-3’ 
353 bp 
R 5’-ATACGGCCAGGCATTGAAGT-3’ 
Exons 5-6 
F 5’-TGTTCACTTGTGCCCTGACT-3’ 
467 bp 
R 5’-TTAACCCCTCCTCCCAGAGA-3’ 
Exon 7 
F 5’-CTTGCCACAGGTCTCCCCAA-3’ 
237 bp 
R 5’-AGGGGTCAGAGGCAAGCAGA-3’ 
Exons 8-9 
F 5’-TTGGGAGTAGATGGAGCCT-3’ 
445 bp 
R 5’-AGTGTTAGACTGGAAACTTT-3’ 
Exon 10 
F 5’-CAATTGTAACTTGAACCATC-3’ 
260 bp 
R 5’-GGATGAGAATGGAATCCTAT-3’ 
Exon 11 
F 5’-AGACCCTCTCACTCATGTGA-3’ 
245 bp 
R 5’-TGACGCACACCTATTGCAAG-3’ 
F: Forward; R: Reverse. 
 
The amplification of exons 2 and 3 was performed with two different primer sets 
because there is a polymorphism in this region that hinders DNA amplification/sequencing. 
PCR reactions were performed in a thermocycler [Gene Amp PCR Systern 9700, Perkin-EImer, Waltham, 
Massachusetts, USA] according to the conditions of Table III.2 for the second primer set of Table 
III.1 and according to the conditions of Table III.3 for the remaining primer sets used during 
this work. 
 
Table III.2. PCR program used for amplification of exons 2-3 of the TP53 gene 
Temperature Time 
94ºC 
94ºC 
64ºC 
72ºC 
72ºC 
4ºC 
10 Minutes 
30 Seconds 
45 Seconds 
45 Seconds 
10 Minutes 
Pause 
 
Table III.3. PCR program used for amplification of the remaining exons of TP53 
Temperature Time 
94ºC 
94ºC 
63ºC1 
72ºC 
94ºC 
60ºC 
72ºC 
72ºC 
4ºC 
2 Minutes 
30 Seconds 
45 Seconds 
  1 Minute 
30 Seconds 
45 Seconds 
  1 Minute 
5 Minutes 
Pause 
1 -0.5ºC every 3 cycles 
20 Cycles 
30 Cycles 
50 Cycles 
  Materials and Methods 
23 
Amplified PCR products were then analyzed by high-resolution capillary 
electrophoresis in a QIAxcel Advanced system [QUIAGEN, Hilden, Germany] and the electrophoresis 
results were analyzed using the QIAxcel ScreenGel software [QUIAGEN].  
Before the sequencing reaction, the PCR amplification products were purified using 
the ExoSAP-IT method to remove excess of primers, salts, enzymes and dNTPs from the 
previous reaction. Samples were purified adding 2 μL of ExoSAP solution (Exonuclease I 
[Thermo Fisher Scientific, Waltham, Massachusetts, USA] (20 U/μL) and Fast Thermosensitive Alkaline 
Phosphatase [Thermo Fisher Scientific] (1 U/μL), in a proportion of 1:2) to 5 μL of the PCR product, 
followed by incubation at 37ºC for 50 minutes, and enzyme inactivation at 80ºC for 15 
minutes. 
The purification was followed by the sequencing reaction in which the BigDye® 
Terminator v3.1 Cycle Sequencing Kit [Applied Biosystems] was used. The reaction consisted on 
mixing 3.4 μL of sequencing buffer, 0.5 μL of BigDye® Terminator v3.1 (containing dNTPs, 
ddNTPs-fluorocromes, MgCl2 and Tris-HCl buffer), 0.32 μL of one of the corresponding 
primer (forward or reverse), bidestilled sterile water [B. Braun] and 1 μL of the previously 
purified DNA to reach a final reaction volume of 10 μL. The sequencing reaction was 
performed according to the conditions of Table III.4. 
 
Table III.4. PCR program of sequencing reaction 
Temperature Time 
95ºC 
95ºC 
50ºC 
60ºC 
60ºC 
4ºC 
4 Minutes 
10 Seconds 
10 Seconds 
  2 Minutes 
10 Minutes 
Pause 
 
 
In order to remove excess of dNTPs, labeled ddNTPs, and non-incorporated 
primers, the sequencing products were purified with IIlustra Sephadex® G-50 fine [GE Healthcare, 
Life Sciences, Cleveland, USA], according to standard procedures. After purification, 15 μL of Hi-DiTM 
Formamide [Applied Biosystems] were added to the sequencing products to help stabilize the single 
stranded DNA. The products were then analyzed in a 3500 Genetic Analyzer [Applied Biosystems] 
by capillary electrophoresis. The electropherograms of each sample were analyzed with the 
Sequencing Analysis Software v5.4 [Applied Biosystems]. All of them were examined at least twice, 
reviewed manually and with the Mutation Surveyor® DNA Variant Analysis Software v4.0.8 
[Softgenetics, State College, PA, USA] by two independent observers. 
Approximately 75% of disease-causing mutations can be identified in exons 5 to 8 
of the TP53 gene by sequence analysis. Variants identified in the sequence can be 
35 Cycles 
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classified as pathogenic mutations, benign variants, or variations of uncertain clinical 
significance (Ganguly and Chen, 2016). All TP53 variants described are according to the 
LRG_321 (NM_006231.3) and to the Human Genome Variations Society guidelines. The 
polymorphisms found in TP53 gene were not reported. 
  
 
III.3 Gene-panel Analysis by Next-Generation Sequencing 
Screening for germline mutations in a panel of 94 genes associated with cancer 
predisposition (Table III.5) was performed by next-generation sequencing in 36 peripheral 
blood samples. For this purpose, the Nextera DNA transposome [Illumina, San Diego, CA, USA] was 
used to convert input genomic DNA (gDNA) into adapter-tagged indexed libraries. 
Approximately 50 ng of input gDNA was used in the tagmentation process, which involves 
simultaneous fragmentation and adapter tagging of gDNA followed by adapter ligation.  
 
Table III.5. Trusight Cancer gene list 
Genes 
AIP 
ALK 
APC 
ATM 
BAP1 
BLM 
BMPR1A 
BRCA1 
BRCA2 
BRIP1 
BUB1B 
CDC73 
CDH1 
CDK4 
CDKN1C 
CDKN2A 
CEBPA 
CEP57 
CHEK2 
CYLD 
DDB2 
DICER1 
DIS3L2 
EGFR 
EPCAM 
ERCC2 
ERCC3 
ERCC4 
ERCC5 
EXT1 
EXT2 
EZH2 
FANCA 
FANCB 
FANCC 
FANCD2 
FANCE 
FANCF 
FANCG 
FANCI 
FANCL 
FANCM 
FH 
FLCN 
GATA2 
GPC3 
HNF1A 
HRAS 
KIT 
MAX 
MEN1 
MET 
MLH1 
MSH2 
MSH6 
MUTYH 
NBN 
NF1 
NF2 
NSD1 
PALB2 
PHOX2B 
PMS1 
PMS2 
PRF1 
PRKAR1A 
PTCH1 
PTEN 
RAD51C 
RAD51D 
RB1 
RECQL4 
RET 
RHBDF2 
RUNX1 
SBDS 
SDHAF2 
SDHB 
SDHC 
SDHD 
SLX4 
SMAD4 
SMARCB1 
STK11 
SUFU 
TMEM127 
TP53 
TSC1 
TSC2 
VHL 
WRN 
WT1 
XPA 
XPC 
 
 
 The tagmented DNA was purified by Sample Purification Beads [Illumina], and then it 
was analyzed by high-resolution capillary electrophoresis in a QIAxcel Advanced system 
[QUIAGEN]. The electrophoresis results were analyzed using the QIAxcel ScreenGel software 
[QUIAGEN]. 
The purification reaction was followed by the first PCR amplification, in which the 
purified tagmented DNA was amplified and index 1 and index 2 were added. This PCR 
  Materials and Methods 
25 
reaction is required for cluster generation and sequencing. The tagmented DNA was 
amplified in a solution containing 20 µL of Nextera Library Ampification Mix [Illumina], 5 µL of 
Index 1 [Illumina] and 5 µL of Index 2 [Illumina]. PCR reaction was performed in a thermocycler 
[Veriti™ Thermal Cycler, Applied Biosystems] according to the conditions of Table III.6.    
 
Table III.6. PCR program used in the first PCR amplification 
Temperature Time 
72ºC 
98ºC 
98ºC 
60ºC 
72ºC 
72ºC 
10ºC 
3 Minutes 
30 Seconds 
10 Seconds 
30 Seconds 
30 Seconds 
5 Minutes 
Pause 
 
 
The PCR products were purified using the Sample Purification Beads [Illumina] and 
then quantified using a Qubit 2.0 Fluorometer [Invitrogen, Carlsbad, CA, USA]. The quality of the library 
was assessed using the high-resolution capillary electrophoresis in a QIAxcel Advanced 
system [QUIAGEN]. 
Approximately 500 ng of individual libraries were pooled in batches of 12 samples, 
followed by a first hybridization. The reaction consisted on mixing 40 µL of DNA library 
sample, 50 µL of Enrichment Hybridization Buffer [Illumina] and 10 µL of TruSight Content Set 
CSO [Illumina]. This step mixes the DNA library with capture probes to targeted regions of 
interest and it was performed according to the conditions of Table III.7. 
 
Table III.7. PCR program used in the first hybridization 
Temperature Time 
95ºC 10 Minutes  
94ºC1        1 Minute 
58ºC Pause2 
1 -2ºC per cycle 
2 for at least 90 minutes and up to a maximum of 24 hours 
 
The first hybridization was followed by capture of probes hybridized to the target 
regions of interest using streptavidin beads. The biotinylated gDNA fragments bound to the 
streptavidin beads were magnetically pulled down from the solution. The partly enriched 
gDNA fragments were then eluted from the beads and subjected to a second round of 
hybridization and second capture.  
The capture library was purified by Sample Purification Beads [Illumina], which was 
followed by a second PCR amplification. The capture library was amplified in a solution 
10 Cycles 
18 Cycles 
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containing 5 µL of PCR Primer Cocktail [Illumina] and 20 µL of Nextera Enrichment 
Amplification Mix [Illumina]. PCR reaction was performed in a thermocycler [Veriti™ Thermal Cycler, 
Applied Biosystems] according to the conditions of Table III.8. 
 
Table III.8. PCR program used in the second PCR amplification 
Temperature Time 
72ºC 
98ºC 
98ºC 
60ºC 
72ºC 
72ºC 
10ºC 
3 Minutes 
30 Seconds 
10 Seconds 
30 Seconds 
30 Seconds 
5 Minutes 
Pause 
 
 
The PCR products were purified using the Sample Purification Beads [Illumina].  The 
tagged and amplified sample libraries were quantified using a Qubit 2.0 Fluorometer [Invitrogen] 
and the quality of the library was checked using the high-resolution capillary electrophoresis 
in QIAxcel Advanced system [QUIAGEN]. The pools were diluted to 4 nM in a final volume of 
10 µL with HT1 (Hybridization Buffer) [Illumina] and subsequently joined 5 µL of each pool. The 
pooled library (12 pM) was loaded and sequenced on the MiSeq platform [Illumina], according 
to the manufacturer’s instructions. 
The trimmed FASTQ files were generated using MiSeq Reporter [Illumina]. Reads were 
aligned against the whole-genome build Isaac Enrichment v.2.1 [Illumina]. All variants found 
were confirmed by Sanger sequencing using the primer sequences of the respective genes 
(Table III.9). 
 
Table III.9. Primers used for PCR of BRCA2 exons 23-24 and FANCA exon 4  
Gene Region 
amplified 
Direction Primer pairs 
Product 
length 
BRCA2 Exons 23-24 
F 5’-TCCACTACTAATGCCCACAAAGAGA-3’ 
613 bp 
R 5’- CAAATTTGCCAACTGGTAGCTCC-3’ 
FANCA Exon 4 
F 5’-AGGTGTTGCCACCAGTTTTATTG-3’ 
404 bp 
R 5’-CAGCTTAAAAGTAACAACGGGCA -3’ 
F: Forwrad; R: Reverse. 
 
The BRCA2 mutation was described according to the LRG_293 (NM_000059.3) and 
the FANCA mutation was described according to the LRG_495 (NM_000135.2), both taking 
into account the Human Genome Variation Society guidelines. The polymorphisms found 
were not reported. 
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III.4 Fluorescence In Situ Hybridization in Tissue Sections 
Screening of HER2 amplification was performed by Fluorescence In Situ 
Hybridization (FISH) in sections from paraffin-embedded tumor from patients with germline 
variants. Slides were deparaffinized in two passages through xylol, followed by other two 
passages through 100% ethanol, 5 minutes each. For pre-treatment, slides were incubated 
in 2x SSC for 3 minutes, followed by the incubation with NaSCN 1M at 80ºC for 10 minutes 
and then rinsed in 2xSSC for 2 minutes. The enzymatic digestion was made through 
incubation of a pepsin solution (4mg/mL) with each slide at 37ºC for 6 minutes. In order to 
finish the digestion, the slides were placed two times in a 2xSSC solution for 2 minutes 
each, followed by an increasing series of ethanols, 70%, 85% and 100%, for 2 minutes 
each. After dehidratation, the specific probe sets were applied onto each sample. The HER2 
probe was combined with a centromeric probe for chromosome 17 (ON ERBB2 Her-2/Neu 
(17q12) / SE 17, Kreatech). Slides were placed in a ThermoBrite denaturation/hybridization 
system (Leica Biosystems, Nussloch, Germany) and co-denaturated at 80ºC for 8 minutes, 
followed by hybridization for 18 hours at 37ºC. The slides were then washed in a 
2xSSC/0.5% IGEPAL (Sigma Aldrich) solution at 74º for 5 minutes and 2XSSC/0.1% 
IGEPAL at room temperature (RT) for 3 minutes. Finally, slides were counterstained with 
4’, 6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, Burlingame, California, USA).  
The slides were analyzed and fluorescent images corresponding to DAPI, Spectrum 
Green and Spectrum Orange were automatically captured in a GSL-120 Automated 
Cytogenetics Platform with a CytoVision Software Version number 7.4 (Leica Biosystems). 
For amplification scoring the image processing uses a fixed Modal Average (ModeSA) of 
0.25 microns squared (µm²) for the reference size of a test signal. CytoVision image 
processing evaluates the signal size, breaking up large or clustered signals greater than 0.5 
µm² by dividing by 0.25 to calculate the signal count. 
Results were evaluated according to ASCO/CAP recommendations for HER2 
testing in breast cancer (Wolff et al., 2013). HER2 gene amplification by FISH assay was 
performed in the invasive component of a breast cancer specimen. Amplification in a dual-
probe FISH assay was defined by examining first the HER2/CEP17 ratio followed by the 
average HER2 copy number. If there was a second contiguous population of cells with 
increased HER2 signals per cell, and this cell population consists of more than 10% of tumor 
cells on the slide (defined by image analysis or visual estimation of the slide), a separate 
counting was also performed. 
A ratio of average HER2 and centromeric probe signals of at least two representative 
non overlapping cancer cell populations (at least 60 cells) were computed for each sample. 
Cases were categorized as negative for HER2 amplification whenever HER2/CEP17 < 2.0 
with an average HER2 copy number < 4.0 signals/cell, and as having HER2 amplification 
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when HER2/CEP17 ≥ 2.0 or HER2/CEP17 < 2.0 with an average HER2 copy number ≥ 6.0 
signals/cell. Cases were categorized as equivocal when HER2/CEP17 < 2.0 with an 
average HER2 copy number ≥ 4.0 and < 6.0 signals/cell. 
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IV. Results 
 
IV.1 TP53 Germline Variants in the Retrospective Cohort 
DNA samples from 88 women with HER2-positive invasive breast cancer were 
screened for germline mutations in all coding exons of the TP53 gene (exons 2 to 11) by 
Sanger sequencing. Three heterozygous variants (Table IV.1) were found in three cases, 
corresponding to a frequency of TP53 germline variants of 3.41% in this retrospective 
cohort.  
 
Table IV.1. Germline variants found in the TP53 gene 
Sample 
number 
cDNA 
description 
Protein 
description 
Exon 
number 
Effect Biological Significance 
#32 c.642T>G p.(His214Gln) Exon 6 Missense VUS 
#60 c.524G>A p.(Arg175His) Exon 5 Missense Pathogenic 
#72 c.559+19_559+35del p.? Intron 5 Intronic VUS 
VUS: Variant of uncertain significance 
 
IV.1.1 Evaluation of TP53 variants 
The first variant consists of a nonsynonymous substitution of a Thymine for a 
Guanine (transversion, c.642T>G) in the third position of codon 214 (CAT → CAG), 
resulting in a nonconservative substitution of a Histidine for a Glutamine, p.(His214Gln) 
(figure IV.1a). This variant has already been described (Kakudo et al., 2005; Lacroix et al., 
2006), but the disease-association remains unclear and is therefore classified as a variant 
of uncertain significance (VUS) for the time being. 
The second variant consists of a nonsynonymous substitution of a Guanine for an 
Adenine (transversion, c.524G>A) in the second position of codon 175 (CGC → CAC), 
resulting in a nonconservative substitution of an Arginine for a Histidine, p.(Arg175His) 
(figure IV.1b). This variant occurs in a mutation hotspot and is classified as a deleterious 
mutation (Freed-Pastor and Prives, 2012; Kakudo et al., 2005).  
The third variant consists of a deletion of 17 base pairs (c.559+19_559+35del) in 
intron 5 (figure IV.1c). This variant has not yet been included in any databases, such as 
COSMIC (Catalogue of Somatic Mutations in Cancer), Ensemble, LOVD (Leiden Open 
Variation Database) or IARC TP53 databases and is therefore classified as a VUS.  
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Figure IV.1. DNA sequence electropherograms obtained from peripheral blood samples: a. TP53 
c.524G>A, p.(Arg175His); b. TP53 c.642T>G, p.(His214Gln); c. TP53 c.559+19_559+35del, p.?. 
 
IV.1.2 Clinicopathological Characteristics of TP53 variant carriers 
Patient #32, with the TP53 variant c.642T>G, p.(His214Gln), is a woman who was 
diagnosed at age 26 years with an invasive ductal breast carcinoma, grade III. 
Immunohistochemical analysis showed negative expression of estrogen and progesterone 
receptors, and HER2 was classified as 3+. According to the TNM classification, the tumor 
stage was pT2N2M0. The patient had previously been tested for germline mutation in 
BRCA1 and BRCA2 genes and did not present any mutation. This patient has no family 
history of cancer, as it is shown in the pedigree (Figure IV.2a).  
Patient #60, with the TP53 mutation c.524G>A, p.(Arg175His), is a woman who was 
diagnosed at age 31 years with a medullary carcinoma, grade III. Immunohistochemical 
analysis showed negative expression of estrogen and progesterone receptors, and HER2 
was classified as 3+. According to the TNM classification, the tumor stage was pT1N0M0. 
The patient's peripheral blood had previously been tested for mutations in BRCA1 and 
BRCA2 genes and three VUS in the BRCA1 gene were found. This patient’s family 
comprises many relatives affected with gastric, colon, pancreas and breast tumors. From 
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the mother's side, there are three relatives in the first-degree and one relative in second-
degree affected with gastric cancer at a young age; in the father's side has a cousin affected 
with breast cancer at a young age and grandmother with colon cancer (Figure IV.2b). 
Patient #72, with the TP53 variant c.559+19_559+35del, is a woman who was 
diagnosed at age 35 years with an invasive ductal breast carcinoma, grade III. 
Immunohistochemical analysis showed positive expression of estrogen receptor (75-
100%), positive expression of progesterone receptor (50-75%), and HER2 was classified 
as 3+. According to the TNM classification, the tumor stage was pT2N0(sn). The patient's 
peripheral blood had previously been tested for BRCA1 and BRCA2 Portuguese founder 
mutations and the results were negative. This patient has no family history of cancer (Figure 
IV.2c). 
 
 
Figure IV.2. Pedigrees of the three patients with germline variants in the TP53 gene in the retrospective 
series: a. patient #32; b. patient #60; c. patient #72 
 
 
IV.2 Germline Mutation Spectrum in the Prospective Cohort 
DNA samples from 36 women with HER2-positive invasive breast cancer were 
screened by next-generation sequencing for germline mutations in 94 genes known to play 
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a role in cancer predisposition. Four heterozygous variants (Table IV.2) were found in four 
cases.  
Table IV.2. Germline variants found by next-generation sequencing 
Sample 
number 
Gene 
cDNA 
description 
Protein description 
Exon 
number 
Effect 
Biological 
Significance 
#93 BRCA2 c.9105T>A p.(Tyr3035Ter) Exon 23 Nonsense Pathogenic 
#104 TP53 c.383delC p.(Pro128LeufsTer42) Exon 5 Frameshift Pathogenic 
#107 FANCA c.295C>T p.(Gln99Ter) Exon 4 Nonsense Pathogenic 
#122 TP53 c.935C>G p.(Thr312Ser) Exon 9 Missense VUS 
VUS: Variant of uncertain significance  
 
IV.2.1 Evaluation of Germline Carriers 
Patient #93 presents a mutation in the BRCA2 gene consisting of a nonsynonymous 
substitution of a Thymine for an Adenine (transversion, c.9105T>A) in the third position of 
codon 3035 (TAT → TAA) and resulting in a nonsense mutation: p.(Tyr3035Ter) (Figure 
IV.3a). This mutation has not yet been included in any database, such as the COSMIC or 
Ensemble databases, but by its nature and localization it is classified as pathogenic. 
Patient #104 has a mutation in the TP53 gene consisting of a deletion of a Cytosine 
(c.383delC) in the second position of codon 128 (CCT → C-T) and resulting in a frameshift 
deletion: p.(Pro128LeufsTer42) (Figure IV.3b). This mutation was reported in the COSMIC 
database as a somatic event in breast invasive carcinoma, but by its nature it is classified 
as pathogenic.  
In Patient #107 a mutation in the FANCA gene was found. This mutation consists of 
a nonsynonymous substitution of a Cytosine for a Thymine (transversion, c.295C>T) in the 
first position of codon 99 (CAG → TAG), resulting in a nonsense mutation: p.(Gln99Ter) 
(Figure IV.3c). This mutation has been described in unrelated Spanish Gypsy patients with 
Fanconi anemia (Callen et al., 2005; Gille et al., 2012) in which it is considered deleterious. 
Patient #122 presents a variant in the TP53 gene consisting of a nonsynonymous 
substitution of a Cytosine for a Guanine (transversion, c.935C>G) in the second position of 
codon 312 (ACC → AGC) and resulting in a nonconservative substitution of a Threonine for 
a Serine: p.(Thr312Ser) (Figure IV.3c). This variant has been described as having an 
uncertain biological significance by ClinVar and LOVD databases. 
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Figure IV.3. DNA sequence electropherograms obtained from peripheral blood samples: a. BRCA2 
c.9105T>A, p.(Tyr3035Ter); b. TP53 c.383delC, p.(Pro128LeufsTer42); c. FANCA c.295C>T, 
p.(Gln99Ter); d. TP53 c.935C>G, p.(Thr312Ser). 
 
IV.2.2 Clinicopathological Characteristics of Variant Carriers 
Patient #93, with the BRCA2 mutation c.9105T>A, p.(Tyr3035Ter), is a woman who 
was diagnosed at age 30 years with an invasive micropapillary carcinoma, grade III. 
Immunohistochemical analysis showed positive expression of estrogen receptor (75-
100%), positive expression of progesterone receptor (75-100%), and HER2 was classified 
as 2+ (amplification was confirmed by FISH). According to the TNM classification, the tumor 
stage was pT1cN0(sn)Mx. This patient presented scant family history of cancer, namely a 
maternal uncle affected with gastric cancer at age 54 years, and a second-degree cousin 
affected with breast cancer at age 40 years (Figure IV.4a).  
Patient #104, with the TP53 mutation c.383delC, p.(Pro128LeufsTer42), is a woman 
who was diagnosed at age 33 years with an invasive ductal breast carcinoma, grade III. 
This woman had previously been diagnosed with contralateral breast cancer at age 29 
years, but the HER2 status of this first tumor is unknown. Immunohistochemical analysis 
showed positive expression of estrogen and progesterone receptors, and HER2 was 
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classified as 3+. According to the TNM classification, the tumor stage was cT1N0M0. This 
patient presents family history of early-onset cancer, namely, a sister with three primary 
tumors (teratoma, breast and colon cancer, respectively at ages 19, 25 and 33) the father 
with lung cancer at age 40, and a paternal grandmother who died with an unspecified 
gynecologic cancer (Figure IV.4b).  
Patient #107, with the FANCA mutation c.295C>T, p.(Gln99Ter), is a woman who 
was diagnosed at age 29 years with an invasive ductal breast carcinoma, grade III. 
Immunohistochemical analysis showed positive expression of estrogen receptor (30%), 
positive expression of progesterone receptor (25%), and HER2 was classified as 3+. This 
patient presented scant family history of cancer, with only the paternal grandmother with 
thyroid cancer at age 70 years (Figure IV.4c).  
Patient #122, with the TP53 variant c.935C>G, p.(Thr312Ser), is a woman who was 
diagnosed at age 38 years with an invasive micropapillary carcinoma, grade II/III. 
Immunohistochemical analysis showed positive expression of estrogen receptor (75-
100%), positive expression of progesterone receptor (1-10%), and HER2 was classified as 
2+ (amplification was confirmed by FISH). According to the TNM classification, the tumor 
stage was cT3N1M0. This patient has family history of cancer, namely two paternal aunts 
with breast cancer at age 50 years (Figure IV.4d).  
 
 
Figure IV.4. Pedigrees of the four patients positive for germline variants in BRCA2, TP53 or FANCA 
genes in the prospective cohort: a. patient #93; b. patient #104; c. patient #107; d. patient #122 
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IV.3 Pattern of HER2 Amplification in Mutations Carriers 
HER2 amplification was screened by dual-probe FISH (HER2 and CEP17 probes) 
in seven tumors from patients with germline variants. The results are summarized in Table 
IV.3 and illustrated by Figure IV.5. 
 
Table IV.3. HER2 amplification in paraffin-embedded tumor 
Sample number IHC HER2 signal CEP17 signal HER2/CEP17 % amplified cells 
VUS in TP53 
#32 3+ 13.40 5.10 2.63 100 
#72 3+ 9.72 2.80 3.47 90 
#122 2+ 6.80 2.93 2.32 80 
Pathogenic Mutations in TP53 
#60 3+ 10.32 2.47 4.18 100 
#104 3+ 9.62 2.55 3.77 100 
Pathogenic Mutations in BRCA2 
#93 2+ 5.33 2.62 2.04 76.6 
Pathogenic Mutations in FANCA 
#107 3+ 7.70 2.12 3.64 100 
 VUS: Variant of uncertain significance 
 
According to ASCO/CAP recommendations, all cases were classified as HER2-
positive (HER2/CEP17 ≥ 2.0). The patients with HER2 test result as equivocal by IHC (2+) 
(#93 and #122) had ratios by FISH lower than patients with 3+ by IHC. The patients with 
pathogenic mutation in the TP53 gene (#60 and #104) presented higher ratios than the 
other patients.
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Figure IV.5. Representative FISH images from 7 tumors from patients with germline variants: a. patient 
#32; b. patient #72; c. patient #122; d. patient #60; e. patient #104; f. patient #93; g. patient #107. 
Green corresponds to CEP17 signals and red corresponds to HER2 signals.  
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V. Discussion 
 
Some data in recent years have suggested that the proportion of HER2-positive 
breast cancer is much higher in Li-Fraumeni syndrome patients than that in sporadic or 
Hereditary breast/ovarian cancer patients (Lee et al., 2012; Melhem-Bertrandt et al., 2012; 
Wilson et al., 2010), but the limited data available indicates that germline TP53 mutations 
may have a limited overall contribution to early-onset HER2-positive disease (Rath et al., 
2013). The identification of germline TP53 mutations carriers is essential for offering them 
screening or prophylactic measures appropriate for their high breast cancer risk (Sorrell et 
al., 2013) and no formal recommendations yet exist in the genetic testing criteria taking into 
consideration this clinicopathological association. Therefore, this study aimed to identify the 
contribution of germline TP53 mutations for early-onset HER2-positive breast cancer, to 
identify other genes with germline mutations in patients with early-onset HER2-positive 
breast cancer, to define the genetic testing criteria to complement established 
recommendations, and to compare the HER2 amplification pattern in women with 
deleterious TP53 germline mutations compared with that in women with other germline 
mutations. We identified five germline variants in the TP53 gene (5/124 = 4.03%) and two 
truncating germline mutations in other genes (2/36 = 5.56%) in patients diagnosed with 
HER2-positive breast cancer diagnosed until the age of 40 years. 
 
 
V.1 Pathogenic Germline Mutations in the TP53 Gene 
In the present work, two pathogenic germline TP53 mutations were found in 124 
patients with HER2-positive breast cancer diagnosed until the age of 40 years (1.6%), 
accounting for two of 79 patients (2.53%) diagnosed before the age of 36 years (one of 
them with a contralateral breast cancer diagnosed before the age of 30 years). The 
deleterious TP53 mutations identified were the c.524G>A, p.(Arg175His), and the 
c.383delC, p.(Pro128LeufsTer42), one identified by Sanger sequencing in the retrospective 
series and the other by NGS in the prospective series of patients. The first mutation is quite 
common and has been described as a mutation hotspot. In breast cancer patients, 
according to the IARC TP53 Database, p.(Arg175His) has been detected as germline 
mutation twenty-one times and the UniProtKB/Swiss-Prot reports that this mutation is 
associated with Li-Fraumeni syndrome. This mutation is able to confer increased 
proliferation, inhibition of apoptosis, invasive ability, and changes in metabolism, among 
others, through the transcriptional activation of target genes (MYC, EGFR, EGR1, NFKB2, 
MMP3, MMP13, CYP24A1, DHCR24, and others) (Freed-Pastor and Prives, 2012). Lacroix 
  Discussion 
42 
and colleagues (2006) also report that this mutation has the ability to strongly inhibit 
transcription of the FAS pro-apoptotic gene (Lacroix et al., 2006). On the other hand, the 
TP53 mutation c.383delC, p.(Pro128LeufsTer42), had only been identified once and it was 
reported as a somatic event (http://cancer.sanger.ac.uk/cosmic). This mutation occurs at 
the beginning of the DNA-binding domain that is essential to protein-DNA interaction and 
encodes a truncated protein with only 168 amino acids, which strongly suggests its 
pathogenicity. The identification of these deleterious mutations establish the genetic 
diagnosis of Li-Fraumeni syndrome in these two families and predictive testing is available 
to relatives. Interestingly, none of these two families comply with the classical clinical criteria 
of Li-Fraumeni syndrome or with the Chompret criteria for germline TP53 testing due to the 
lack of other cancers typical of this syndrome, but both index cases have first degree 
relatives with early-onset and/or multiple primary cancers, which are features that fit well 
with the genetic diagnosis. 
The study of Rath et al. (2013), the only one in the literature having early-onset 
HER2-positive breast cancer as the primary selection criterion, evaluated the prevalence of 
germline TP53 mutation in a cohort of 213 women with HER2-positive breast cancer 
diagnosed before 50 years, and found three patients with germline mutation in TP53 (ages 
at diagnosis of 23, 32, 44 years) (1.4%) (Rath et al., 2013). Among the 40 women diagnosed 
before 36 years with HER2-positive breast cancer, two had mutation in the TP53 gene (5%) 
(Rath et al., 2013). Our study found two germline TP53 pathogenic mutations among 79 
women diagnosed with (2.53%). Although our study was more restrictive regarding the age 
of diagnosis (before 40 years), it included almost double the number of patients HER2-
positive breast cancer diagnosed before age 35, so the proportion we report may be closer 
to reality in this setting. 
 
 
V.2 Variants of Uncertain Significance in the TP53 Gene 
In addition to the clearly deleterious mutations, we found also three variants of 
uncertain significance in the TP53 gene, namely, c.642T>G, p.(His214Gln), 
c.559+19_559+35del, p.?, and c.935C>G, p.(Thr312Ser) (3/124 = 2.4%). The missense 
variant c.642T>G, p.(His214Gln), has already been reported as a somatic event in four 
sporadic carcinomas of the esophagus, cervix uteri, sinuses and colon (http://p53.iarc.fr/), 
but never as a germline change. Some studies reported that the variant p.His214Gln has 
higher ability to induce apoptosis than the wild-type p53 and it has been referred to as a 
super p53 (Kakudo et al., 2005; Lacroix et al., 2006). These studies and the absence of 
history of cancer in the relatives of our patient with this variant question the pathogenicity 
of this variant, although we have not yet excluded that it is a de novo variant. On the other 
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hand, the variant c.559+19_559+35del has never been reported before and it occurs in 
intron 5 away from the highly conserved 5’ splice site. The Human Splice Finder program 
predicts that this deletion does not have an impact on splicing activity 
(http://www.umd.be/HSF3/), suggesting that this variant might have no impact on the 
biological activity of the protein. The patient with this variant is the only affected with cancer 
in her family, a fact that reinforces the nondeleterious nature of this variant or its low 
penetrance (if it did not occur de novo). Finally, the missense variant c.935C>G, 
p.(Thr312Ser), has already been reported as a somatic event in four sporadic neoplastic 
samples of the lung, ovary, mouth and hematopoietic system (http://p53.iarc.fr/), but never 
as a germline change. No study has yet addressed the biological significance of this variant 
and our patient has only two second-degree relatives affected with breast cancer at an older 
age. In fact, there is a striking difference regarding cancer history in first-degree relatives 
between the two patients with clearly deleterious TP53 mutations and these three patients 
with VUS. Further segregation data on a research basis or determination of its de novo 
nature may contribute to a better evaluation of these variants, which at this stage have no 
clinical relevance for these families and cannot be used for predictive testing. 
 
 
V.3 BRCA2 Germline Mutation in HER2-positive Breast Cancer 
The BRCA2 mutation c.9105T>A, p.(Tyr3035Ter) has never been reported in the 
scientific literature or in databases. This mutation is predicted to result in a truncated protein 
with only 3034 amino acids (the BRCA2 wild-type contains 3418 amino acids), if the mutated 
mRNA is not affected by nonsense mediated decay. Although this mutation is quite distal, 
there are other downstream deleterious mutations described in the BRCA2 gene, such as 
the c.9924C>G, Y3308X (Kuznetsov et al., 2008), something that strongly supports its 
pathogenic nature. A mutation in this gene was unexpected since BRCA1/BRCA2-
associated tumors rarely overexpress or show amplification of HER2. In the large study 
from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), only 10% of BRCA1 
mutation carriers and 13% of BRCA2 mutation carriers had HER2-positive tumors 
(Mavaddat et al., 2012), percentages that are much lower than that in sporadic breast 
carcinomas. This is supported by our own data in our population, where only 5% of BRCA1 
and 10% of BRCA2 index breast cancer patients had HER2-positive carcinomas (Peixoto 
et al., 2015). 
According to the NICE guidelines, genetic testing of the BRCA1/BRCA2 genes 
should be offered when the a priori likelihood of a germline mutation in these genes is equal 
or higher than 10% (Evans et al., 2013). In the patient in whom we found a BRCA2 mutation, 
the combined mutation probability is well below the 10% threshold, both using the 
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BRCAPRO Bayesian calculation  (Berry, 2002) and the updated Manchester score (which 
includes a penalization for HER2+ tumors). This relatively low likelihood is further supported 
by the fact that only one of the 36 patients (2.8%) tested with NGS in this study was shown 
to carry a deleterious BRCA1/BRCA2 mutation. This means that, in this case, we would 
normally offer testing only for the Portuguese founder mutations in the BRCA1/BRCA2 
genes, which represent nearly 50% of the mutations in our population, a strategy that 
reduces the likelihood of missing a deleterious mutation to about 5% (Peixoto et al., 2015). 
Therefore, this BRCA2 mutation was found only because the proband was included in this 
study for TP53 mutation analysis by gene-panel NGS, highlighting the potential of NGS to 
increase the molecular diagnosis yield in situations in which different syndromes have 
overlapping clinical features (for example, Hereditary breast/ovarian cancer and Li-
Fraumeni syndromes) and in which genetic testing criteria do not have 100% sensitivity 
(Pinto et al., 2016). Another example of overlapping clinicopathological features between 
different syndromes is provided the patient with a deleterious TP53 mutation that presented 
a medullary breast carcinoma, a relatively rare histological subtype that is strongly 
associated with germline BRCA1 mutations (Mavaddat et al., 2012; Peixoto et al., 2015). 
However, this medullary breast carcinoma was atypical for being HER2-positive. 
 
 
V.4 FANCA Mutation in Early-onset HER2-positive Breast Cancer 
The mutation identified in FANCA, c.295C>T, p.(Gln99Ter), results in a predicted 
truncated protein with only 98 amino acids (the FANCA wild-type contains 1455 amino 
acids). This mutation has been found in homozygosity in unrelated Spanish Gypsy patients 
with Fanconi anemia (Callen et al., 2005; Gille et al., 2012), therefore demonstrating that it 
is deleterious. Although an initial study suggested that mutations in Fanconi anemia genes 
other than BRCA2 (FANCD1) would not be associated with increased risk of breast cancer 
(Seal et al., 2003), it is today clear that heterozygous truncating mutations in PALB2 
(FANCN), another gene that causes Fanconi anemia when biallelic inactivating mutations 
occur, significantly increases the risk of breast cancer. Antoniou and co-workers (2014) 
reported that the risk of breast cancer for female PALB2 mutation carriers, as compared 
with the general population, was eight to nine times as high among those younger than 40 
years of age (Antoniou et al., 2014), resulting in cumulative penetrance that is similar to that 
of BRCA mutations, especially in the presence of family history of breast cancer. Mutations 
in other FANC genes are so rare that a clear evidence of their association with breast cancer 
and robust penetrance estimates are lacking (Kleibl and Kristensen, 2016). Interesting in 
this context is the study of Solyom and co-workers (2011), who assessed the FANCA gene 
for breast cancer susceptibility and identified a novel heterozygous deletion removing the 
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promoter and 12 exons in a single family (Solyom et al., 2011). Our finding of one truncating 
mutation in 36 patients (2.8%) tested by NGS, a frequency that is similar to those of TP53 
and BRCA2 mutations, indicates that a more extensive evaluation of the association of 
FANCA mutations with breast cancer susceptibility is required, namely through the inclusion 
of this gene in NGS panels used for genetic testing of breast cancer patients. 
 
 
V.5 Genetic Testing Criteria of Early-onset HER2-positive Breast Cancer 
Since the initial description of the Li-Fraumeni syndrome, several criteria have been 
suggested to identify high-risk families (McCuaig et al., 2012; Sorrell et al., 2013). The 
classic clinical criteria for Li-Fraumeni syndrome require families with proband diagnosed 
with sarcoma before age 45, and a first-degree relative with cancer before age 45, and also 
another first- or second-degree relative with any cancer diagnosed under age 45 or with 
sarcoma at any age (Li et al., 1988). On the other hand, more sensitive but less specific 
criteria are used for selecting patients for germline TP53 testing, the most commonly used 
being the revised Chompret criteria. These criteria require families with proband diagnosed 
with a tumor belonging to the Li-Fraumeni syndrome spectrum (soft tissue sarcoma, 
osteosarcoma, brain tumor, premenopausal breast cancer, adrenocortical carcinoma, 
leukemia, lung bronchoalveolar cancer) before age 46 and at least one first- or second 
degree relative with a Li-Fraumeni syndrome cancer (except breast if the proband has 
breast cancer) under the age of 56 years or with multiple tumors at any age; or proband 
with multiple primary tumors (except multiple breast), two of which belong to the Li-
Fraumeni syndrome tumor spectrum and the first of which occurred before age 46; or 
proband with adrenocortical carcinoma or choroid plexus tumor at any age, irrespective of 
family history (Gonzalez et al., 2009; McCuaig et al., 2012). Both patients identified in this 
work with a pathogenic mutation in the TP53 gene did not meet these testing criteria, leaving 
room to recommend the use of less stringent criteria that takes in consideration also the 
HER2 status in breast cancer patients.  
Of note, patient #60 has several relatives affected with early-onset gastric cancer, a 
cancer that has been observed before in the context of Li-Fraumeni syndrome (Horio et al., 
1994; Pinto et al., 2009; Varley, 2003), especially in countries with high gastric cancer 
incidences (Pinto et al., 2009). Portugal is a high-risk country for gastric carcinoma with an 
incidence of 13.1 new cases per 100 000 inhabitants per year (IARC, GLOBOCAN 2012), 
so this tumor type should perhaps also be considered in the genetic testing criteria in our 
population. Furthermore, both probands with deleterious TP53 mutations in this study, 
besides early-onset HER2-positive breast cancer, have first degree relatives with early-
onset and/or multiple primary cancers. Based on literature (McCuaig et al., 2012) and our 
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data, we propose that TP53 germline testing should be offered also to patients that, even if 
not complying with the Chompret criteria, present HER2-positive breast cancer diagnosed 
until the age 35 with at least one first-degree relative with cancer before age 45 (including 
tumors that do not belong to the Li-Fraumeni syndrome spectrum), as well as to all cases 
of breast cancer diagnosed before the age of 30 irrespective of family history (to take into 
account the frequent occurrence of de novo mutations in the TP53 gene and the fact that 
not all breast carcinomas in Li-Fraumeni patients are HER2-positive). 
On the other hand, as discussed above, it is clear that inherited predisposition to 
early-onset HER2-positive breast cancer is not restricted to TP53 mutations, since we found 
a similar proportion of BRCA2 and FANCA deleterious mutations in this study. However, 
we currently see no compelling reason to modify the genetic testing criteria for the 
BRCA1/BRCA2 genes, and more data are required to substantiate the role of FANCA 
mutations in breast cancer predisposition.  
 
 
V.6 Pattern of HER2 Amplification in Carriers of Deleterious TP53 Mutations 
Compared with Those with Other Mutations  
Some studies have suggested that germline TP53 mutations encourage breast 
cancer development along a fairly specific oncogenic pathway that frequently includes 
HER2 amplification and/or overexpression (Masciari et al., 2012; Melhem-Bertrandt et al., 
2012; Wilson et al., 2010). Wilson and co-workers (2010) reported that ten out of twelve 
cases with pathogenic germline TP53 mutations were positive for HER2 (83%), contrasting 
with the percentage of HER2 amplification in sporadic breast cancer (15-20%) (Wilson et 
al., 2010). In another study with more patients, Melhem-Bertrandt and co-workers (2012) 
compared the pathological characteristics of breast tumors from patients testing positive for 
a germline mutation in TP53 gene (n=30) with those of breast tumors from patients testing 
negative (n=79), and found HER2 amplification and/or overexpression in 67% (20/30) of the 
former and 25% in the latter (Melhem-Bertrandt et al., 2012). Finally, Masciari and co-
workers (2012) sought to complement the existing small literature with histopathologic 
analysis of breast cancers from women with Li-Fraumeni syndrome, and reported that 63% 
(20/32) of the invasive breast cancers and 73% (8/11) of DCIS were positive for HER2 
(Masciari et al., 2012).  
According to the latest ASCO/CAP guidelines, positive HER2 status is defined as a 
score of 3+ by IHC, a HER2/CEP17 ratio of 2.0 or more by dual-probe ISH, as well as an 
average HER2 copy number of ≥ 6.0 signals per cell even when the HER2/CEP17 ratio is 
below 2.0 (Wolff et al., 2013). In routine clinical practice the most common approach for 
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HER2 testing is to screen for protein overexpression with IHC (Mano et al., 2007), a strategy 
that was also followed routinely at our institution. In fact, of the cases with germline variants, 
only the two cases classified as 2+ by IHC had previously been tested by FISH. To the best 
of our knowledge, the issue of whether the pattern of HER2 amplification in carriers of 
deleterious TP53 mutations is different from those without has not been addressed before. 
We therefore decided to test all cases with germline variants with the same quantitative 
software analysis of digital images in order to compare the HER2 amplification pattern in 
breast carcinomas from patients with pathogenic TP53 germline mutations with that of 
patients with other germline mutations. We found that, while amplification was confirmed in 
all cases, the highest HER2 amplification ratios were detected in the breast carcinomas 
from patients with deleterious TP53 germline mutations, followed closely by that of the 
breast carcinoma in the truncating FANCA mutation carrier. Conversely, the lowest 
amplification ratio was seen in the breast carcinoma of the patient with the BRCA2 germline 
mutation, whereas the breast tumors from patients TP53 VUS showed intermediate 
amplification scores. However, we have so far analyzed only a few breast carcinomas of 
patients with germline variants (n=7), so clearly more data are necessary to conclusively 
show if such differences are real. 
HER2-positive breast cancers are currently treated with a humanized monoclonal 
antibody, trastuzumab, alone or coupled to emtansine, a cytotoxic agent (T-DM1). An 
alternative therapy is based on a small molecule tyrosine kinase inhibitor, lapatinib. Despite 
the remarkable effectiveness of these therapies, breast cancers frequently become 
resistant, resulting in disease progression (Vicario et al., 2015; Wolff et al., 2013). HER2 
overexpression is routinely used to predict response to anti-HER2 therapy and only patients 
with a score of 3+ in IHC and gene amplification should receive anti-HER2 therapy. It has 
been demonstrated that tumors with moderate HER2 (2+) expression without gene 
amplification do not respond to trastuzumab therapy (Eggemann et al., 2015). We can 
therefore speculate that patients with higher degree of HER2 amplification in their tumors 
might respond better to anti-HER2 therapies when compared with patients with lesser 
degrees of amplification, although increasing levels of amplification under treatment with 
anti-HER2 therapy might theoretically be a mechanism of resistance. Be that as it may, 
Vicario and co-workers (2015) showed that gene amplification in double minutes occurs in 
approximately 30% of HER2-positive breast tumors and that the loss of HER2 protein 
expression due to loss of double minutes containing HER2 isn’t a likely mechanism of 
resistance to anti-HER2 therapies, since the number of double minutes containing HER2 is 
maintained in different models of resistance to anti-HER2 therapies (Vicario et al., 2015). 
Further studies are therefore needed to identify the mechanism of HER2 amplification 
pattern in breast carcinomas of Li-Fraumeni patients, as well as to find out if their response 
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to anti-HER2 targeted therapies differs from that of other patients with HER2-positive breast 
cancer.  
 
 
  
 
 
 
 
 
 
 
 
VI. CONCLUSION 
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VI. Conclusion 
 
After the completion of this study we conclude that: 
 
 Deleterious germline TP53 mutations are present in about 1.6% of patients with 
HER2-positive breast cancers diagnosed until the age of 40 years, and in 2.5% of 
those diagnosed before the age of 36 years; 
 Other genes besides TP53 are involved in predisposition to early-onset HER2-
positive breast cancer, namely BRCA2 and FANCA; 
 TP53 germline testing should be extended beyond those complying with the 
Chompret criteria, namely, to those presenting HER2-positive breast cancer 
diagnosed until the age of 35 with at least one first-degree relative with any cancer 
before age 45, as well as to all cases of breast cancer diagnosed before age 30 
irrespective of family history; 
 Breast carcinomas from patients with deleterious TP53 germline mutations might 
show higher HER2 amplification ratios than those from patients with other germline 
variants. 
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VII. Future Perspectives 
 
This study may benefit from further analysis to support our conclusions and to allow 
a more specific evaluation of the genes with germline mutations in patients with early-onset 
HER2-positive breast cancer. Thus, we plan:  
 
 To complete segregation analysis in order to obtain more data for better 
pathogenicity evaluation of the identified variants; 
 To extend the gene panel NGS study to a larger series of patients with early-onset 
HER2-positive breast carcinomas in order to establish the mutation frequency in 
other genes besides TP53; 
 To extend the HER2 amplification analysis by FISH to carcinomas from more 
mutation carriers, including from families already with genetic diagnosis of Li-
Fraumeni syndrome; 
 To test the HER2 amplification pattern in breast carcinomas from patients without 
germline variants and with similar age at diagnosis, to be used as controls for 
comparison with that of variant carriers. 
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